Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 390 participants.

Also called NCT06788626

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 390 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06788626
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06788626. Randomized; single masking; primary purpose treatment. Start 2025-02 (anticipated); primary completion 2028-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
Acronym
GALLOP2
Condition
Acute Ischemic Stroke
Condition
Large Vessel Occlusion
Condition
Neuroprotective Drugs
Condition
Endovascular Treatment
Intervention (Drug)
Semaglutide 0.5 mg
Intervention (Other)
Standard medical treatment
Lead sponsor
Wei Hu (class: other)
Collaborator
Chinese University of Hong Kong (class: other)

Record details

Record id
cardio:ct-nct06788626
Content hash
163c27e84aab0a4ee6e16144287b65dd623956b7180c8eef4dab08e78a9b0e13